Department of Molecular Medicine, Faculty of Advanced Technologies in Medicine, Iran University of Medical Sciences (IUMS), Tehran, Iran.
Department of Molecular Medicine, Oncopathology Research Center, Faculty of Advanced Technologies in Medicine, Iran University of Medical Sciences, Tehran, Iran.
Syst Rev. 2017 Dec 19;6(1):262. doi: 10.1186/s13643-017-0660-y.
Breast cancer is one of the most common types of cancer in women worldwide. Recent studies have provided strong support for the cancer stem cell (CSC) hypothesis, which suggests that many cancers, including breast cancer, are driven by a subpopulation of cells that display stem cell-like properties. The hypothesis that a subpopulation of circulating tumor cells (CTCs) possesses many CSC-like hallmarks is reinforced by the expression of related molecular markers between these two cell populations. The aim of this study is to systematically review primary studies and identify circulating CSC markers in breast cancer patients.
Relevant observational studies evaluating the expression of circulating breast cancer stem cell markers through October 31, 2016, will be searched in PubMed, SCOPUS, Embase, ISI Web of Science, and Google Scholar with no restriction on language. Full copies of articles identified by the search and considered to meet the inclusion criteria will be obtained for data extraction and synthesis. Two quality assessment tools will be used for evaluating observational studies like case control, which are the Hoy et al. suggested tool and Newcastle-Ottawa Scale (NOS), respectively. Publication bias will be assessed by funnel plots or Egger's test (i.e., plots of study results against precision), and data synthesis will be performed using Stata software (Stata Corp V.12, TX, USA).This systematic review will be reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA).
Detecting cancer stem cells in blood will help clinicians to monitor cancer patients by obtaining as many samples as needed with a non-invasive method and in any stages; it is not possible to repeat sampling on working on tissue samples. By identifying cancer stem cells early in blood, it will be possible to distinguish metastasis in early stages.
CRD42016043810.
乳腺癌是全世界女性最常见的癌症类型之一。最近的研究为癌症干细胞（CSC）假说提供了强有力的支持，该假说表明，包括乳腺癌在内的许多癌症是由具有干细胞样特性的细胞亚群驱动的。循环肿瘤细胞（CTC）的亚群具有许多与 CSC 样特征相关的分子标记这一假设，也得到了这两种细胞群体之间表达相关分子标记的支持。本研究旨在系统地综述原始研究，并确定乳腺癌患者的循环 CSC 标志物。
将在 PubMed、SCOPUS、Embase、ISI Web of Science 和 Google Scholar 中搜索截至 2016 年 10 月 31 日评估通过循环乳腺癌干细胞标志物表达的观察性研究，不限制语言。通过搜索确定并认为符合纳入标准的文章的全文副本将被获取以进行数据提取和综合。将使用 Hoy 等人建议的工具和纽卡斯尔-渥太华量表（NOS）两种质量评估工具分别评估病例对照等观察性研究。将通过漏斗图或 Egger 检验（即研究结果与精度的关系图）评估发表偏倚，并使用 Stata 软件（StataCorp V.12，TX，USA）进行数据综合。本系统评价将根据系统评价和荟萃分析的首选报告项目（PRISMA）进行报告。
在血液中检测癌症干细胞将有助于临床医生通过非侵入性方法在任何阶段获得尽可能多的样本来监测癌症患者；在组织样本上重复采样是不可能的。通过早期在血液中识别癌症干细胞，有可能在早期阶段区分转移。
CRD42016043810。
